Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients

Chinese Journal of Lung Cancer

Volumn 14, Issue 4, 2011, Pages 340-344

  Gao, Zhiqiang ^a   Han, Baohui ^a   Shen, Jie ^a   Gu, Aiqin ^a   Zhong, Hua ^a  

^a SHANGHAI CHEST HOSPITAL   (China)

Author keywords

Curative effect; Lung neoplasms; Prognosis; Protein expression; RRMl

Indexed keywords

CISPLATIN; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 79955080528     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2011.04.07     Document Type: Article

References (8)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59(4): 225-249.
2. Aggarwal C, Somaiah N, Simon GR, et al. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Cane Netw, 2010, 8(7): 822-832.
3. Arora A, Siddiqui IA, Shukla Y, et at Modulation ofp53 in 7,12-dimethylbenz[a] anthracene-induced skin tumors by diallyl sulfide in Swiss albino mice. Mol CancerTher, 2004, 3(11): 1459-1466.
4. Adams VR, Harvey RD. Histological and genetic markers for non-small-cell lung cancer: customizing treatment based on individual tumor biology. Am J Health Syst Pharm, 2010, 67(1 Suppl l): S3-S9.
5. Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine. Ann Oncol, 2006, 17(suppl 5): vl3-vl6
6. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small cell lung cancer. Oncogene, 2003, 22(23): 3548-3553.
7. Lee JJ, Maeng CH, Baek SK, et al The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit Ml (RRMl) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). Lung Cancer, 2010, 70(2): 205-210.
8. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small cell lung cancer treated with cisplatin and gemcitabine. Ann One, 2006, 17(12): 1818-1825.